Titan Global Balanced Fund

FUND AIMS AND OBJECTIVES

The Titan Global Balanced Fund's main objective is to generate capital growth by investing into a combination of fixed income and global equities. The underlying investments are selected using a thematic investment process. Titan Global Balanced Fund is a sub-fund of the Titan Global Investment Fund; an open-ended, multiclass Unit Trust authorised as a Class B Scheme by the Guernsey Financial Services Commission.

INVESTMENT BREAKDOWN

- 25 Global Themes
- 23 Regional Equities
- 15 Corporate Bonds
- 14 Global Equities
- 10 Specialist
- 7 High Yield Bonds
- 3 Short Dated Bonds
- 3 Cash & Equivalents

PERFORMANCE CHART



COMMENTARY

The Titan Global Balanced Fund returned +0.8% in June, bringing its year-to-date performance to +7.8%. By comparison, the ARC Balanced PCI returned an estimated +0.8%, advancing +4.6% year to date.

Global stock markets finished broadly flat in June, which failed to highlight the significant variations across regions and sectors. In sector news, artificial intelligence and semiconductor shares suffered a sharp sell-off early in the month, arguably due to profit taking. The sector later recovered fuelled by a renewed appetite for tech names following SpaceX's historic public debut. Despite political uncertainty from UK leadership changes and a hawkish interest rate outlook from the US Federal Reserve, global markets ultimately proved resilient.

As part of continuous reviews of the underlying positions, we have been focusing on healthcare over recent months. The sector has faced short-term headwinds, largely reflecting uncertainty in respect to the regulatory environment, changing US policies and negative investor sentiment. However, we continue to view the long-term opportunity positively, due to structural growth drivers such as an ageing population, rising healthcare spending and continued innovation. The review resulted in two new positions.

Polar Global Healthcare Select which invests in 30–40 large-cap healthcare companies across subsectors including pharmaceuticals, healthcare providers and medical technology. Key holdings include Eli Lilly, UnitedHealth, AstraZeneca and Novo Nordisk. Polar Biotechnology on the other hand focuses on innovative biotechnology businesses, with exposure to companies developing next-generation therapies, diagnostics and life sciences tools. The portfolio includes names such as Argenx, Revolution Medicines, Xenon Pharmaceuticals, AstraZeneca and Madrigal Pharmaceuticals.

After a difficult period for the biotech sector, returns have improved meaningfully over the last 12 months, helped by renewed investor appetite for innovation-led growth and stronger performance from companies with robust clinical pipelines and identifiable catalysts. As biotech tends to exhibit higher levels of volatility, in return for outsized growth potential over the long-term, the position has been sized accordingly within the Fund. The blend of the two provides diversified exposure within an acceptable risk profile and together, they provide useful diversification away from some of the portfolio's existing growth exposures and the current technology/AI trade, which is dominating markets.

CUMULATIVE PERFORMANCE

	1 Month	3 Month	6 Month	YTD	1 Year	3 Year	5 Year
Titan Global Balanced O Acc	0.8%	8.8%	7.8%	7.8%	15.2%	29.8%	20.7%

Past performance is not a reliable guide to future performance and may not be repeated. Source: FE fundinfo. Data date: 30/06/2026.

PRIOR CALENDAR YEARS' PERFORMANCE

	2025	2024	2023	2022	2021
Titan Global Balanced O Acc	8.5%	6.0%	5.7%	-8.8%	4.3%

All performance figures are based on the "O" class. Figures are in GBP and includes capital returns and any income. Figures are net of all fees charged within the fund and any underlying third party funds. If you invest via an intermediary additional charges may apply.

Financial promotion - the value of the Fund may go down as well as up - you may get back less than you invested.

PORTFOLIO HOLDINGS

Fund	Weight
Global Equities	**13.6%**
Titan Global Blue Chip	5.4%
Titan Global Quality Leaders	4.1%
Vanguard Global Stock Index	4.1%
Regional Equities	**22.9%**
iShares MSCI Japan	2.1%
Jupiter UK Alpha	3.7%
Jupiter Japan Select	2.0%
Vanguard FTSE 100	3.8%
Vanguard FTSE Developed Europe	3.0%
Vanguard S&P 500	5.5%
Waverton European Capital Growth	2.8%
Global Themes	**25.4%**
BlueBox Global Technology	5.7%
KBI Global Sustainable Infrastructure	2.9%
Pacific North of South EM Equity Income	4.1%
Polar Capital Artificial Intelligence	4.7%
Polar Capital Asian Stars	5.3%
Polar Capital Biotechnology	0.6%
Polar Capital Global Healthcare Select	2.1%
Coporate Bonds	**15.3%**
Titan Core Credit	4.8%
Titan Hybrid Capital	4.8%
Vontobel TwentyFour Strategic Income	5.7%
High Yield Bonds	**6.6%**
Royal London Sterling Extra Yield	1.9%
Schroder Strategic Credit	4.7%
Short Dated Bonds	**3.6%**
iShares Ultrashort	3.6%
Specialist	**9.6%**
Fermat Cat Bond	4.9%
Ruffer Total Return	4.7%
Cash & Equivalents	**3.0%**
Cash	3.0%
	100.0%

FUND DETAILS

Dealing Frequency: Daily, UK business days
Settlement Period: T+4
Fund Assets: £289.2 Mil

CLASSES

Name	Annual Charge	OCF*	Min. investment	ISIN
Titan Global Balanced I Acc	1.50%	2.29%	£5,000	GG00B3F15Q93
Titan Global Balanced O Acc	0.75%	1.54%	£5,000	GG00BYSYNZ76
Titan Global Balanced O Inc	0.75%	1.54%	£5,000	GG00BMHKT541

*Ongoing Charge Figure includes annual charge, fund expenses and costs within underlying investments.

DIVIDEND INFORMATION

Pay Date	O Inc
30/10/2025	£1.56
30/04/2026	£1.69
Yield: 2.91%	

INVESTMENT MANAGER

Titan Wealth (CI) Limited
20 New Street, St Peter Port, Guernsey, GY1 2PF
T: +44 1481 888070
E: funds@titanwci.com

KEY PARTIES

Administrator:
Apex Fund and Corporate Services (Guernsey) Limited
1 Royal Plaza, Royal Avenue, St. Peter Port, Guensey, GY1 2HL
T: +44 1481 737600 E: titanfunds@apexgroup.com

Trustee: BNP Paribas Securities Services S.C.A. Guernsey Branch
Custodian: BNP Paribas Securities Services S.C.A. Guernsey Branch
Auditor: Grant Thornton Channel Islands

Platform Availability:

7IM, AllFunds, Bank Capital International, FNZ, Novia, Old Mutual International, Pershing and Praemium